Clinical Trial Update: An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients [Phase 3]

View source ↗

Summary

This document reports an open-label safety extension of SLV308 in early Parkinson's disease as part of the S308.3.003 Phase 3 trial. The study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SLV308

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Early Stage Parkinson's Disease | Phase 3 | Status: COMPLETED